Skip to main content
padlock icon - secure page this page is secure

Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics

Buy Article:

$68.00 + tax (Refund Policy)

Drug response is a complex process determined by both genetic and non-genetic factors. Factors that control drug response can be divided into those that affect the systemic distribution and the concentration of drug at its target (pharmacokinetics) and those associated with drug targets and cellular downstream effectors (pharmacodynamics). Most pharmacogenetic studies to date have focused on the influence of genetic variation in determinants of drug distribution. Consistent associations between host polymorphisms in drug metabolising enzymes, including UGT1A1, TPMT and DPD and patient toxicity or response to chemotherapies have been demonstrated. Less is known about the cellular events following exposure to anticancer agents that lead to DNA repair or cell death, making them more difficult to study. Genetic variation in these downstream effectors is a potential source of interindividual differences in tumoral response. Exciting associations between tumor sensitivity to tyrosine kinase inhibitors and somatic mutations in their drug targets (for example epidermal growth factor receptor (EGFR)) have recently been demonstrated. These findings take us closer to personalized therapy. This paper reviews the latest advances in cancer pharmacogenetics with an emphasis on genetic variation in drug targets and mediators of cellular events that occur following drug-target interactions.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anemia; chemotherapy; microsatellite instability; polymorphism; tandem repeat in the enhancer region (TSER)

Document Type: Research Article

Affiliations: Washington University School of Medicine, 660 S. Euclid Avenue, Box 8069, St Louis MO 63110, USA.

Publication date: March 1, 2006

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more